Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
In: Calderon , M A , Demoly , P , Casale , T , Akdis , C A , Bachert , C , Bewick , M , Bilò , B M , Bohle , B , Bonini , S , Bush , A , Caimmi , D P , Canonica , G W , Cardona , V , Chiriac , A M , Cox , L , Custovic , A , De Blay , F , Devillier , P , Didier , A , Di Lorenzo , G , Du Toit , G , Durham , S R , Eng , P , Fiocchi , A , Fox , A T , van Wijk , R G , Gomez , R M , Haathela , T , Halken , S , Hellings , P W , Jacobsen , L , Just , J , Tanno , L K , Kleine-Tebbe , J , Klimek , L , Knol , E F , Kuna , P , Larenas-Linnemann , D E , Linneberg , A , Matricardi , M , Malling , H J , Moesges , R , Mullol , J , Muraro , A , Papadopoulos , N , Passalacqua , G , Pastorello , E , Pfaar , O , Price , D , Del Rio , P R , Ruëff , R , Samolinski , B , Scadding , G K , Senti , G , Shamji , M H , Sheikh , A , Sisul , J C , Sole , D , Sturm , G J , Tabar , A , Van Ree , R , Ventura , M T , Vidal , C , Varga , E M , Worm , M , Zuberbier , T & Bousquet , J 2016 , ' Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project ' , Clinical and Translational Allergy , vol. 6 , 41 . https://doi.org/10.1186/s13601-016-0131-x
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; Peer reviewed
In: Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T. and Bousquet, J. (2016). Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clin. Transl. Allergy, 6. LONDON: BMC. ISSN 2045-7022
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
In: Calderon , M A , Demoly , P , Casale , T , Akdis , C A , Bachert , C , Bewick , M , Bilò , B M , Bohle , B , Bonini , S , Bush , A , Caimmi , D P , Canonica , G W , Cardona , V , Chiriac , A M , Cox , L , Custovic , A , De Blay , F , Devillier , P , Didier , A , Di Lorenzo , G , Du Toit , G , Durham , S R , Eng , P , Fiocchi , A , Fox , A T , van Wijk , R G , Gomez , R M , Haathela , T , Halken , S , Hellings , P W , Jacobsen , L , Just , J , Tanno , L K , Kleine-Tebbe , J , Klimek , L , Knol , E F , Kuna , P , Larenas-Linnemann , D E , Linneberg , A , Matricardi , M , Malling , H J , Moesges , R , Mullol , J , Muraro , A , Papadopoulos , N , Passalacqua , G , Pastorello , E , Pfaar , O , Price , D , del Rio , P R , Ruëff , R , Samolinski , B , Scadding , G K , Senti , G , Shamji , M H , Sheikh , A , Sisul , J C , Sole , D , Sturm , G J , Tabar , A , van Ree , R , Ventura , M T , Vidal , C , Varga , E M , Worm , M , Zuberbier , T & Bousquet , J 2016 , ' Allergy immunotherapy across the life cycle to promote active and healthy ageing : From research to policies ' , Clinical and Translational Allergy , vol. 6 , 41 . https://doi.org/10.1186/s13601-016-0131-x
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.)
